NCT03707587View on ClinicalTrials.gov

M7824 in People With Recurrent Respiratory Papillomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

October 29, 2019

Study Completion Date

July 6, 2022

Conditions
Recurrent Respiratory PapillomatosisRespiratory PapillomatosisLaryngeal Papilloma, RecurrentHuman Papilloma Virus
Interventions
DRUG

M7824

Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03707587 - M7824 in People With Recurrent Respiratory Papillomatosis | Biotech Hunter | Biotech Hunter